Unnatural Amino Acid Incorporation onto Adenoviral (Ad) Coat Proteins Facilitates Chemoselective Modification and Retargeting of Ad Type 5 Vectors

ABSTRACT Surface modification of adenovirus vectors can improve tissue-selective targeting, attenuate immunogenicity, and enable imaging of particle biodistribution, thus significantly improving therapeutic potential. Currently, surface engineering is constrained by a combination of factors, including impact on viral fitness, limited access to functionality, or incomplete control over the site of modification. Here, we report a two-step labeling process involving an initial metabolic placement of a uniquely reactive unnatural amino acid, azidohomoalanine (Aha), followed by highly specific chemical modification. As genetic modification of adenovirus is unnecessary, vector production is exceedingly straightforward. Aha incorporation demonstrated no discernible impact on either virus production or infectivity of the resultant particles. “Click” chemical modification of surface-exposed azides was highly selective, allowing for the attachment of a wide range of functionality. Decoration of human adenovirus type 5 (hAd5) with folate, a known cancer-targeting moiety, provided an ∼20-fold increase in infection of murine breast cancer cells (4T1) in a folate receptor-dependent manner. This study demonstrates that incorporation of unnatural amino acids can provide a flexible, straightforward route for the selective chemical modification of adenoviral vectors.

[1]  M. Mccaman,et al.  Quantitation of adenovirus DNA and virus particles with the PicoGreen fluorescent Dye. , 1999, Analytical biochemistry.

[2]  Glen R. Nemerow,et al.  Visualization of α-Helices in a 6-Ångstrom Resolution Cryoelectron Microscopy Structure of Adenovirus Allows Refinement of Capsid Protein Assignments , 2006, Journal of Virology.

[3]  D. Curiel,et al.  Fiber-modified adenoviruses for targeted gene therapy. , 2008, Methods in molecular biology.

[4]  P. Stewart,et al.  Insights into adenovirus host cell interactions from structural studies. , 2009, Virology.

[5]  S. Dewhurst,et al.  Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v)beta3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens. , 2006, Vaccine.

[6]  M. Barry,et al.  Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  Roberto Marabini,et al.  Localization of the N-terminus of minor coat protein IIIa in the adenovirus capsid. , 2008, Journal of molecular biology.

[8]  G. Schoehn,et al.  The C-Terminal Domains of Adenovirus Serotype 5 Protein IX Assemble into an Antiparallel Structure on the Facets of the Capsid , 2008, Journal of Virology.

[9]  A. Rivera,et al.  Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach , 2008, Virology Journal.

[10]  Y. Mikyas,et al.  Postentry Neutralization of Adenovirus Type 5 by an Antihexon Antibody , 2004, Journal of Virology.

[11]  P. Stewart,et al.  CryoEM structure at 9A resolution of an adenovirus vector targeted to hematopoietic cells. , 2005, Journal of molecular biology.

[12]  M. Magnusson,et al.  Genetic retargeting of adenovirus vectors: functionality of targeting ligands and their influence on virus viability , 2002, The journal of gene medicine.

[13]  D. Curiel,et al.  Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus , 2007, Gene Therapy.

[14]  T. Park,et al.  Folate immobilized and PEGylated adenovirus for retargeting to tumor cells. , 2006, Bioconjugate chemistry.

[15]  Partha Sarathi Banerjee,et al.  Chemoselective attachment of small molecule effector functionality to human adenoviruses facilitates gene delivery to cancer cells. , 2010, Journal of the American Chemical Society.

[16]  Joo‐Hang Kim,et al.  Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[17]  D. Curiel,et al.  Targeted gene delivery by tropism-modified adenoviral vectors , 1996, Nature Biotechnology.

[18]  P. Low,et al.  Folate-targeted therapeutic and imaging agents for cancer. , 2009, Current opinion in chemical biology.

[19]  M. Finn,et al.  Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold. , 2005, Bioconjugate chemistry.

[20]  S. Cusack,et al.  A quasi‐atomic model of human adenovirus type 5 capsid , 2005, The EMBO journal.

[21]  D. Curiel,et al.  Transductional targeting of adenovirus vectors for gene therapy , 2006, Cancer Gene Therapy.

[22]  Florian Kreppel,et al.  Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  M. Magnusson,et al.  Adenovirus type 5 fiber knob domain has a critical role in fiber protein synthesis and encapsidation. , 2006, The Journal of general virology.

[24]  S. Kochanek,et al.  Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  Y. Mikyas,et al.  Flexibility of the Adenovirus Fiber Is Required for Efficient Receptor Interaction , 2003, Journal of Virology.

[26]  C. Miller,et al.  Characterization of an Adenovirus Vector Containing a Heterologous Peptide Epitope in the HI Loop of the Fiber Knob , 1998, Journal of Virology.

[27]  Matthew L. Baker,et al.  Cryoelectron Microscopy of Protein IX-Modified Adenoviruses Suggests a New Position for the C Terminus of Protein IX , 2006, Journal of Virology.

[28]  R. Alemany.  Designing adenoviral vectors for tumor-specific targeting. , 2009, Methods in molecular biology.

[29]  David T. Curiel,et al.  Engineering targeted viral vectors for gene therapy , 2007, Nature Reviews Genetics.

[30]  Carolyn R Bertozzi,et al.  Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Curiel,et al.  Modulation of Adenovirus Vector Tropism via Incorporation of Polypeptide Ligands into the Fiber Protein , 2002, Journal of Virology.

[32]  C. Balagué,et al.  Replicative adenoviruses for cancer therapy , 2000, Nature Biotechnology.

[33]  M. Barry,et al.  Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  R. M. Burnett,et al.  Structural and Phylogenetic Analysis of Adenovirus Hexons by Use of High-Resolution X-Ray Crystallographic, Molecular Modeling, and Sequence-Based Methods , 2003, Journal of Virology.

[35]  D. Brough,et al.  Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins , 1997, Journal of virology.

[36]  D. Nowotnik,et al.  Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. , 2004, Journal of inorganic biochemistry.